Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 9/20 | 0.57 |
| ▸ | CDK4 | P11802 | 4/20 | 0.56 |
| ▸ | CCND1 | P24385 | 4/20 | 0.56 |
| ▸ | GPX4 | P36969 | 1/20 | 0.55 |
| ▸ | FAAH | O00519 | 3/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL997738 | 0.95 | TRPV1 (0.51) | TRPV1CDK4CCND1GPX4FAAH | |
| SCHEMBL999215 | 0.75 | MAPT (0.52) | MEN1KMT2A | |
| SCHEMBL8401917 | 0.75 | BAZ2B (0.64) | TRPV1CDK4CCND1GPX4HDAC6 | |
| SCHEMBL13942708 | 0.75 | CDK4 (0.89) | TRPV1CDK4CCND1FAAH | |
| SCHEMBL20882095 | 0.74 | GPX4 (0.77) | TRPV1CDK4CCND1GPX4FAAH | |
| SCHEMBL13942707 | 0.73 | CDK4 (0.71) | TRPV1CDK4CCND1GPX4FAAH | |
| SCHEMBL13255322 | 0.73 | GPX4 (0.67) | TRPV1CDK4CCND1GPX4FAAH | |
| SCHEMBL997010 | 0.73 | TRPV1 (1.00) | TRPV1MEN1KMT2A | |
| SCHEMBL999252 | 0.72 | TRPV1 (0.80) | TRPV1CDK4CCND1 | |
| SCHEMBL5556447 | 0.72 | GPX4 (0.77) | TRPV1CDK4CCND1GPX4FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060154944-A1 | Novel tricyclic heterocycle compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-07-13 | — | — | US | claimed |
| EP-1637521-A1 | NOVEL TRICYCLIC HETEROCYCLE COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-03-22 | — | — | EP | claimed |
| EP-1637521-B1 | NOVEL TRICYCLIC HETEROCYCLE COMPOUND | ONO PHARMACEUTICAL CO (JP) | 2013-06-19 | — | — | EP | disclosed |
| US-7872133-B2 | Tricyclic heterocycle compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-01-18 | — | — | US | disclosed |
| US-20060154944-A1 | Novel tricyclic heterocycle compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-07-13 | — | — | US | disclosed |
| EP-1637521-A1 | NOVEL TRICYCLIC HETEROCYCLE COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-03-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154944-A1 | Novel tricyclic heterocycle compound | CYP11B1, CYP11B2, HCCS | TRPV1 2437/4885CDK4 987/4885CCND1 316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.